Importantly, we previously developed a monomeric FGF2-based conjugate that exhibited high toxicity against FGFR1-overproducing cancer cells in vitro and showed efficient tumor growth retardation in an FGFR-positive human breast cancer xenograft model in mice [63]. The gene discussed is FGFR1; the disease is cancer.